Immupharma PLC Enterprise Investment Scheme Status (1727D)

TIDMIMM

RNS Number : 1727D

Immupharma PLC

27 January 2015

FOR IMMEDIATE RELEASE: FULL RNS 27 JANUARY 2015

IMMUPHARMA

Advance Assurance Received from H M Revenue and Customs Regarding

"Enterprise Investment Scheme" Status

ImmuPharma PLC (AIM: IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qualify for Enterprise Investment Scheme (EIS) status.

EIS offers a range of tax reliefs to investors who invest in qualifying companies. These tax reliefs would be available provided that the individual and the Company continue to meet the rules of the Scheme at the time of the investment and for a period of 3 years subsequently.

Commenting on the agreement, Richard Warr, ImmuPharma's Executive Chairman, said: "We are pleased to have received this advanced assurance from HM Revenue and Customs. Qualifying for EIS gives ImmuPharma access to the broadest range of potential investors and investment funds."

ENDS

For further information please contact:

 
                                           + 44 (0) 20 7152 
 ImmuPharma plc                                        4080 
 Dimitri Dimitriou, Chief Executive 
  Officer 
 Dr Robert Zimmer, President 
  and Chief Scientific Officer 
 Richard Warr, Chairman 
  Tracy Weimar, Vice President, 
  Operations and Finance 
 
 
 
 Lisa Baderoon, Head of Investor 
  Relations                            + 44 (0) 7721 413496 
 
 Panmure, Gordon & Co., NOMAD 
  & Broker                             [phone] 
 
 Hugh Morgan 
  Fred Walsh 
  Duncan Monteith 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAXFKADSSEFF